Invest In Denmark May Attract Many Clinical Research Organizations In India

12 Aug 2013

Indian Clinical research organization and bio-pharma are showing keen interest to conduct both on human and animal studies in Denmark.  Due to the indefinite delays related to the permission to conduct the human studies for Indian clinical trials industry, now invest in Denmark is suiting aptly. Certain facilities like single-point-of entry (SPOE) system, which the government of Denmark has put in place makes it easy for the corporate to plan related to recruiting subjects and clinical studies. The SPOE system ensures that processes are standardized and recruitment of the patient is streamlined.

The two critical components that make Indian bio-pharma industry and Indian CROs to consider Denmark are its access to national databases and efficient patient data tracking systems. Dr Ebsen pointed out that in the world to conduct clinical research; Denmark is the third best country after United States and Canada, and the best in Europe.  There is also acceptance and understanding of the Danish population on the importance of clinical trials that makes the Danish patients to participate in human studies. All these factors contribute in making it relatively easy to recruit and obtain consent from eligible study participants.  Over 20,000 people in Denmark participate in clinical trials annually, according to the association of pharmaceutical producers. Dr Ebsen said due to the favorable factors, big pharma companies have opted for Denmark proving that it is among the preferred countries for clinical trials